Hubert H. Chuang, M.D., Ph.D.
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Diagnostic Radiology - The University of Texas Health Science Center at Houston, Houston, TX
Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, Diagnostic Radiology - The University of Texas Health Science Center at Houston, Houston
Education & Training
Degree-Granting Education
| 2002 | Washington University School of Medicine, St. Louis, MO, USA, PHD, Immunology |
| 2002 | Washington University School of Medicine, St. Louis, MO, USA, MD, Medicine |
| 1992 | Yale University, New Haven, CT, USA, BS, Molecular Biophysics and Biochemistry |
Postgraduate Training
| 2007-2008 | Fellowship in PET/CT, Johns Hopkins University, Baltimore, MD |
| 2005-2007 | Residency in Nuclear Medicine, Montefiore Medical Center, Bronx, NY |
| 2002-2004 | Resident in Internal Medicine, Yale New Haven Hospital, New Haven, CT |
Board Certifications
| 2009 | Certification Board of Nuclear Cardiology |
| 2007 | American Board of Nuclear Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2022
Assistant Professor, Department of Nuclear Medicine, Diagnostic Radiology - The University of Texas Health Science Center at Houston, Houston, TX, 2010 - 2017
Administrative Appointments/Responsibilities
Rotation Site Director, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017
Institutional Committee Activities
Member, Credentials Committee of the Medical Staff, 2018 - Present
Member, Institutional Review Board 5 (IRB 5), 2013 - 2018
Member, DI Functional Educational Committee, 2013 - 2019
Associate Member, Graduate Medical Education Committee, 2013 - 2017
Member, PET/CT QA & Education Committee, 2013 - Present
Member, The University of Texas MD Anderson Cancer Center, Houston, TX, Graduate Medical Education Budget Subcommittee, 2012 - 2014
Associate Member, Institutional Review Board 5 (IRB 5), 2012 - 2013
Member, Graduate Medical Education Committee, 2011 - 2013
Member, DI Radiologist IT Advisory Group, 2011 - 2012
Member, Nuclear Medicine Research Peer Review Committee, 2008 - Present
Honors & Awards
| 2008 | Best Clinical Paper - 2nd Place, Young Professionals Committee, SNM Annual Meeting |
| 2003 | AAAAI Allergic Skin Diseases Research Award, Fujisawa |
| 1996 | American Diabetes Association Medical Student Research Fellowship, 1996, American Diabetes Association |
| 1991 | Humana Foundation Scholarship, Humana Foundation |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2(11):1334-1343, 2018. PMID: 29895624.
- Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leukemia & Lymphoma(1042-8194), 2018.
- Akhtari M, Milgrom SA, Pinnix CC, Reddy JP, Dong W, Smith GL, Mawlawi O, Abou Yehia Z, Gunther J, Osborne EM, Andraos TY, Wogan CF, Rohren E, Garg N, Chuang H, Khoury JD, Oki Y, Fanale M, Dabaja BS. Re-classifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 131(1):84-94, 2018. e-Pub 2017. PMID: 29038339.
- Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-Stage Hodgkin Lymphoma Outcomes After Combined Modality Therapy According to the Post-Chemotherapy 5-Point Score:Can Residual PET-Positive Disease Be Cured with Radiotherapy Alone?. Br J Haematol 179(3):488-496, 2017. e-Pub 2017. PMID: 28832956.
- Christakis I, Vu T, Chuang HH, Fellman B, Figueroa AMS, Williams MD, Busaidy NL, Perrier ND. The diagnostic accuracy of neck ultrasound, 4D-Computed tomography and sestamibi imaging in parathyroid carcinoma. Eur J Radiol 95:82-88, 2017. e-Pub 2017. PMID: 28987702.
- Costelloe CM, Chuang HH, Daw NC. PET/CT of Osteosarcoma and Ewing Sarcoma. Semin Roentgenol 52(4):255-268, 2017. e-Pub 2017. PMID: 28965545.
- Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, Rohren E, Garg N, Chuang HH, Yehia ZA, Reddy JP, Gunther JR, Khoury JD, Suki T, Osborne EM, Oki Y, Fanale M, Dabaja BS. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys 97(2):333-338, 2017. e-Pub 2016. PMID: 28068241.
- Subbiah V, Chuang HH, Gambhire D, Kairemo K. Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics (Basel) 7(1), 2017. e-Pub 2017. PMID: 28212290.
- Salem U, Amini B, Chuang HH, Daw NC, Wei W, Haygood TM, Madewell JE, Costelloe CM. 18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone. J Cancer 8(15):2892-2898, 2017. e-Pub 2017. PMID: 28928879.
- Rydzak C, Chauhan A, Gupta N, Chuang HH, Rohren EM, Bhosale PR. Fat-Containing Hypermetabolic Masses on FDG PET/CT: A Spectrum of Benign and Malignant Conditions. AJR Am J Roentgenol 207(5):1095-1104, 2016. e-Pub 2016. PMID: 27490138.
- Pinnix CC, Shah JJ, Chuang HH, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2015. PMID: 26795083.
- Wang ML, Lee H, Chuang HH, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Dela Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibritinib in combination with Rituximab in Relapsed or Refractory Mantle Cell Lymphoma: A Single-centre, Open-label, Phase 2 Trial. The Lancet Oncology, 2015. PMID: 26640039.
- Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Immunovchemotherapy in the Setting of Response Assessment by (18)fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 1;92(1):113-21, 2015. PMID: 25863759.
- Blonska M, Zhu Y, Chuang HH, You MJ, Kunkalla K, Vega F, Lin X. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood 125(6):981-91, 2015. e-Pub 2014. PMID: 25533033.
- Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL, Macapinlac HA, Chuang HH. Impact of (18)F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging 41(11):2066-73, 2014. e-Pub 2014. PMID: 24990404.
- Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH. The value of (18)F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging 41(9):1756-66, 2014. e-Pub 2014. PMID: 24699907.
- Costelloe CM, Chuang HH, Madewell JE. FDG PET/CT of Primary Bone Tumors. AJR Am J Roentgenol 202(5):W521-31, 2014. PMID: 24848845.
- Oki Y, Chuang HH, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
- Amini B, Madewell JE, Chuang HH, Haygood TM, Hobbs BP, Fox PS, Bassett RL, Costelloe CM. Differentiation of Benign Fluid Collections from Soft-Tissue Sarcomas on FDG-PET/CT. J Cancer 5(5):328-35, 2014. e-Pub 2014. PMID: 24723975.
- Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 54(12):2631-8, 2013. e-Pub 2013. PMID: 23488661.
- Oki Y, Westin JR, Vega F, Chuang HH, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
- Costelloe CM, Chuang HH, Chasen BA, Pan T, Fox PS, Bassett RL, Madewell JE. Bone Windows for Distinguishing Malignant from Benign Primary Bone Tumors on FDG PET/CT. J Cancer 4(7):524-30, 2013. PMID: 23983816.
- Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 5(3):126-42, 2013. PMID: 23671749.
- Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [18F]Fluorodeoxyglucose Positron Emission Tomography-Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case. J Clin Oncol 10(30 26):246-9, 2012. e-Pub 2012. PMID: 22649135.
- Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron Emission Tomography for Assessing Local Failure After Stereotactic Body radiotherapy for Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 83(5):1558-65, 2012. e-Pub 2012. PMID: 22572078.
- Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II Study of Rituximab Plus ABVD in Patients with Newly Diagnosed Classical Hodgkin Lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
- Shkumat NA, Springer A, Walker CM, Rohren EM, Yang WT, Adrada BE, Arribas E, Carkaci S, Chuang HH, Santiago L, Mawlawi OR. Investigating the limit of detectability of a positron emission mammography device: a phantom study. Med Phys 38(9):5176-85, 2011. PMID: 21978062.
- Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clin Nucl Med 36(4):317-9, 2011. PMID: 21368613.
- Hulme KW, Rong J, Chasen B, Chuang HH, Cody DD, Wong FC, Kappadath SC. A CT Acquisition Technique to Generate Images at Various Dose Levels for Prospective Dose Reduction Studies. AJR Am J Roentgenol 196(2):W144 - W151, 2011. PMID: 21257855.
- Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1:80-92, 2010. e-Pub 2010. PMID: 20842228.
- Ayala-Ramirez M, Callender GG, Kupferman ME, Rich TA, Chuang HH, Trent J, Perrier ND, Goodarzi M, Jimenez C. Paraganglioma Syndrome Type 1 in a Patient With Carney-Stratakis Syndrome. Nat Rev Endocrinol 6(2):110-5, 2010. PMID: 20098451.
- Habra MA, Núñez R, Chuang H, Ayala-Ramirez M, Rich T, Kyle K, Jimenez C. Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging. Endocrine 37(1):209-12, 2010. e-Pub 2010. PMID: 20963572.
Invited Articles
- Chuang HH, Macapinlac HA. The Evolving Role of PET-CT in the Management of Esophageal Cancer. Q J Nucl Med Mol Imaging 53(2):201-209, 2009. PMID: 19293768.
Abstracts
- Fanale M, Hagemeister FB, Fayad L, Oki Y, Fowler N, Romaguera J, Shah N, Chuang HH, Feng L, Horowitz SB, Wesson E, Hutto TY, Muzzafar T, Samaniego F, Davis RE. A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. 2014 ASH Annual Meeting, 2014.
- Salem UI, Wei W, Madewell JE, Chuang HH, Amini B, Haygood TM, Costelloe C, Daw BN. 18F-FDG PET/CT as an Indicator of Survival in Bone Primary Ewing Sarcoma. RSNA 100th Scientific Assembly and Annual Meeting, 2014.
- Behrang A, Madewell JE, Chuang HH, Haygood TM, Fox PS, Bassett RL, Costelloe CM. Differentiation of Benign Fluid Collections from Sarcomas on FDG-PET/CT. Texas Radiological Society 99th Annual Scientific Meeting, 2013.
- Wong FC, Schellingerhout D, Rohren E, Vu T, Kappadath CS, Wong S, Chuang HH, Kim E, Guha-Thakurta N, Perrier ND. Localization of Parathyroid Adenomas by Tc99m Sestamibi SPECT-CT, Contrast-enhanced Multi-phase CT (4D-CT) and Combination of SPECT-CT and 4D-CT. RSNA 99th Scientific Assembly and Annual Meeting, 2013.
- Chauhan A, Chuang HH, Jeph S, Rohren EM, Bhosale PR. Fatty Hypermetabolic Masses on FDG PET-CT: A Spectrum of Benign and Malignant Conditions. RSNA 99th Scientific Assembly and Annual Meeting, 2013.
- Khiewvan B, Chelouche Lev D, McCutcheon IE, Slopis JM, Al Sannaa GA, Macapinlac H, Chuang HH. The Value and Therapeutic Impact of 18F-FDG PET/CT in Malignant Peripheral Nerve Sheath Tumors. 2013 Society of Nuclear Medicine & Molecular Imaging Annual Meeting, 2013.
- Takeuchi S, Balachandran A, Habra MA, Phan A, Macapinlac H, Chuang HH. 18F-FDG PET Use in the Management of Adrenocortical Carcinoma. 2013 Society of Nuclear Medicine & Molecular Imaging Annual Meeting, 2013.
- Oki Y, Chuang HH, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. 2012 ASH Annual Meeting, 2012. PMID: 24386943.
- Pan T, Zhang X, Riegel A, Chang J, Chuang HH. Compensation for partial volume effect in PET for treatment response assessment of stereotactic body radiotherapy. Annual Meeting of the Society of Nuclear Medicine, 2011.
- Wong F, Vu T, Duan X, Chuang HH, Schellingerhout D, Kappadath S, Johnson V, Rohren E, Perrier N, Kim EE. Comparison of ultrasonography, Tc-99m sestamibi SPECT-CT and contrast-CT in the localization of parathyroid adenoma. Society of Nuclear Medicine Annual Meeting, 2011.
- Dabaja B, Phan J, Medeiros LJ, Hagemeister FB, Chuang HH, Fayad LE, Shihadeh F, Allen PK, Wogan C, Rodriguez A. Clinical implications of PET-negative residual disease at the completion of chemotherapy for diffuse large B-cell lymphoma. 47th Annual Meeting of the American Society of Clinical Oncology, 2011.
- Zhang X, Balter P, Pan T, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. PET/CT and outcome in lung cancer treated with stereotactic body radiation therapy. ASTRO Annual Meeting. Int J Rad Onc Bio Phy 78(3):S16, 2010.
- Chuang HH, Lodge MA, Wahl RL,. Initial evaluation of respiratory gated PET/CT of upper abdominal lesions. Society of Nuclear Medicine Annual Meeting:108, 2008.
Book Chapters
- Chuang HH, Gradinscak D, Macapinlac HA. Malignancy of Unknown Origin. In: A Case-Based Approach to PET/CT in Oncology. Victor H. Gerbaudo, Editor, 2012.
- Fayad L, Konoplev S, Chuang HH, Rodriguez MA. Aggressive and Highly Aggressive B-Cell Lymphyomas. In: The MD Anderson Manual of Medical Oncology, 2011.
Patient Reviews
CV information above last modified July 31, 2024